SCHEMBL10154103

SCHEMBL10154103

O=P(c1ccccc1)(c1ccccc1)c1cccc2cccc(P(=O)(c3ccccc3)c3ccccc3)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.47
KMT2A Q03164 3/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 5/20 0.43
POLB P06746 3/20 0.43
HTT P42858 3/20 0.43
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA5A P35218 1/20 0.39
MAPT P10636 3/20 0.39
KDM4E B2RXH2 1/20 0.39
APOBEC3A P31941 1/20 0.38
CASP6 P55212 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
LMNA P02545 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 3/20 0.36
TSHR P16473 2/20 0.36
CYP1A2 P05177 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30804581 1.00 NPSR1 (0.47) NPSR1KMT2AMEN1ALDH1A1POLB
SCHEMBL10154151 0.82 NPSR1 (0.42) NPSR1KMT2AMEN1ALDH1A1POLB
SCHEMBL16502276 0.81 NPSR1 (0.38) NPSR1KMT2AMEN1ALDH1A1POLB
SCHEMBL8820834 0.81 NPSR1 (0.44) NPSR1KMT2AMEN1ALDH1A1POLB
SCHEMBL4762963 0.81 POLB (0.52) NPSR1KMT2AMEN1ALDH1A1POLB
SCHEMBL18372021 0.81 NPSR1 (0.46) NPSR1KMT2AMEN1ALDH1A1POLB
SCHEMBL9422307 0.81 POLB (0.47) NPSR1KMT2AMEN1ALDH1A1POLB
SCHEMBL29644308 0.81 POLB (0.47) NPSR1KMT2AMEN1ALDH1A1POLB
SCHEMBL14020795 0.79 NPSR1 (0.52) NPSR1KMT2AMEN1ALDH1A1POLB
SCHEMBL9927357 0.79 NPSR1 (0.45) NPSR1KMT2AMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074925-A1 RARE EARTH COMPLEX SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) 2025-03-06 US disclosed
EP-4365180-A1 RARE EARTH COMPLEX Tosoh Corporation (JP) 2024-05-08 EP disclosed
WO-2023282236-A1 RARE EARTH COMPLEX 東ソー株式会社 2023-01-12 WO disclosed
US-20120211082-A1 PHOTOELECTRIC CONVERSION DEVICE AND SOLAR CELL USING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2012-08-23 US disclosed
US-20120211082-A1 PHOTOELECTRIC CONVERSION DEVICE AND SOLAR CELL USING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2012-08-23 US disclosed
US-20120041203-A1 METAL COMPLEX HAVING AROMATIC RING LIGAND CONTAINING NITROGEN ATOM SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-16 US disclosed
US-20120041203-A1 METAL COMPLEX HAVING AROMATIC RING LIGAND CONTAINING NITROGEN ATOM SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-16 US disclosed
US-20110309304-A1 LUMINESCENT SILVER COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-22 US disclosed
US-20110309304-A1 LUMINESCENT SILVER COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-22 US disclosed
EP-2360162-A1 LUMINESCENT SILVER COMPLEXES Sumitomo Chemical Company, Limited (JP) 2011-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041203-A1 METAL COMPLEX HAVING AROMATIC RING LIGAND CONTAINING NITROGEN ATOM MICA, CD4, CLTC NPSR1 1487/4885KMT2A 2099/4885MEN1 2013/4885
US-20250074925-A1 RARE EARTH COMPLEX L1CAM, CHRM1, NPM1 NPSR1 720/4885KMT2A 3223/4885MEN1 140/4885
US-20110309304-A1 LUMINESCENT SILVER COMPLEX SOD1, AS3MT, GLO1 NPSR1 4577/4885KMT2A 2841/4885MEN1 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.